A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
Merck Sharp & Dohme LLC
Summary
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments * If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART) * If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * If hepatitis C virus (HCV) infected, must have undetectable HCV viral load Exclusion Criteria: * Has active inflammatory bowel disease requiring immunosuppressive…
Interventions
- BiologicalMK-3120
IV infusion
Locations (45)
- The University of Alabama at Birmingham ( Site 1005)Birmingham, Alabama
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)Miami, Florida
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)Hackensack, New Jersey
- NEXT Oncology ( Site 1010)Austin, Texas
- NEXT Oncology ( Site 1011)Houston, Texas
- NEXT Oncology ( Site 1012)Irving, Texas